Targeting pyruvate kinase M2 (PKM2) reduces T cell pathogenicity in multiple sclerosis.

Ellmeier E, Schnabl A, Meissel J, Stracke A, Rittchen S, Stöger L, Passegger CA, Schwarzl L, Tafrali C, Demjaha R, et al.